(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/208100 A1

(51) International Patent Classification:
C07K 16/30 (2006.01) *C07K 5/037* (2006.01)
A61K 38/06 (2006.01) *C07K 16/40* (2006.01)
A61K 38/07 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2025/022153

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/571,291 28 March 2024 (28.03.2024) US
63/736,175 19 December 2024 (19.12.2024) US

(71) Applicant: **MBRACE THERAPEUTICS, INC.** [US/US]; 4660 La Jolla Village Drive, Suite 895, San Diego, California 92122 (US).

(72) Inventors: **STAQUICINI, Fernanda**. **ALLEY, Steve**.


(74) Agent: **CONOUR, John E.**; McDonnell Boehnen Hulbert & Berghoff LLP, 30 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTIBODY-DRUG CONJUGATES AGAINST EPH RECEPTOR A5 (EPHA5) FOR TREATMENT OF CARCINOMA



TBR-Glu-(Val-Cit-PAB-MMAE)-amino-PEG_{24}-Me

FIG. 1

(57) Abstract: The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (*e.g.,* carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

WO 2025/208100 A1